Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.

  title={Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.},
  author={Laura L. Hammitt and Ron Dagan and Yuan Yuan and Manuel Baca Cots and Miroslava N. Bosheva and Shabir Ahmed Madhi and William J Muller and Heather J. Zar and Dennis Brooks and Amy Grenham and Ulrika W{\"a}hlby Hamr{\'e}n and Vaishali S. Mankad and Pin Ren and Therese Takas and Michael E. Abram and Amanda Jane Leach and M. Pamela Griffin and Tonya Villafana},
  journal={The New England journal of medicine},
  volume={386 9},
BACKGROUND Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life. The efficacy and safety of nirsevimab in healthy late-preterm and term infants are uncertain. METHODS We randomly assigned, in a 2:1 ratio, infants who had been born at a gestational age of at least 35 weeks to receive a single intramuscular injection of nirsevimab or… 

Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales

Nirsevimab has the potential to be cost-effective in England and Wales not only for use in high-risk infants but also for use on a case-by-case basis.

Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab

Exposure to palivizumab was associated with a reduction in RSVH rates that was comparable to the reduction seen in controlled clinical trials (weighed mean 4.0-fold reduction), and Immunoprophylaxis should be used in high-risk infants.

RSV disease in infants and young children: Can we see a brighter future?

ABSTRACT Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in children.

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model

An all-infant immunization strategy with nirsevimab could substantially reduce the health and economic burden for US infants during their first RSV season and all infants, including palivizumab-eligible and preterm infants, would benefit from this strategy.

Phase 3 clinical trial results for nirsevimab: Is it time to consider population‐level RSV immunoprophylaxis?

  • C. Mellis
  • Medicine
    Journal of paediatrics and child health
  • 2022
A single-centre prospective cohort study analyses clinical outcomes for 65 preterm very-low-birthweight neonates born to CMV IgG positive mothers, setting the stage for a large multicentred study on the impact of post-natal CMV acquisition via breastmilk including shortand long-term outcomes of pCMV in preterm neonates.

Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)

An update of the current treatment options for acute disease (RSV-specific and -non-specific) and different therapeutic approaches focusing on RSV prevention and the development of new potential vaccines and the successful implementation of passive immunization are provided.

ASSESSMENT Intensified circulation of respiratory syncytial virus (RSV) and associated hospital burden in the EU/EEA

  • Medicine, Biology
  • 2022
Summary In recent weeks, respiratory syncytial virus (RSV) circulation in the EU/EEA has intensified, with increasing transmission rates in all population groups and an earlier-than-usual start of